Fractyl Health Inc. Commo...

1.11
-0.03 (-2.63%)
At close: Apr 04, 2025, 3:59 PM
1.17
5.41%
After-hours: Apr 04, 2025, 05:44 PM EDT

Company Description

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.

Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.

The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Fractyl Health Inc. Common Stock
Fractyl Health Inc. Common Stock logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 107
CEO Dr. Harith Rajagopalan M.D., Ph.D.

Contact Details

Address:
17 Hartwell Avenue
Lexington,
United States
Website https://fractyl.com

Stock Details

Ticker Symbol GUTS
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001572616
CUSIP Number 35168W103
ISIN Number US35168W1036
Employer ID 27-3553477
SIC Code 3841

Key Executives

Name Position
Dr. Harith Rajagopalan M.D., Ph.D. Co-Founder, Chief Executive Officer & Director
Lisa A. Davidson MBA Chief Financial Officer & Treasurer
Dr. Timothy J. Kieffer Ph.D. Chief Scientific Officer
Jay D. Caplan BSEE, MBA Co-Founder, Chief Product Officer & President
Jon Fitzgerald Senior Vice President of Regulatory, Quality & Clinical
Sarah S. Toomey Esq. General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 01, 2025 8-K Current Report
Mar 18, 2025 4/A [Amend] Filing
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 13, 2025 S-3/A [Amend] Filing
Mar 13, 2025 8-K Current Report
Mar 03, 2025 4 Filing